麻豆传媒

Phase I study shows ability to modulate cell signaling

Areal BMD increased when given at the start of maximal estradiol depletion therapy

Further bad news for omega-3 fatty acids in VITAL trial analysis

High or low levels made no difference among healthy people

Large observational databases mitigate concerns about the osteoporosis therapy

Algorithm held its own, but not many study patients were on biologics

Incidence has declined, but burden will increase as older population grows

Same peptide formulated for oral administration passes phase II test

Novel agent, aimed at doing away with adverse metabolic effects, proves mettle in DMD

Updates reflect evidence accumulated in recent years, though research needs remain

Landmark trial throws more cold water on vitamin D, omega-3 pills

Favorable results on most outcomes may suggest poor choice of primary

Weight change in type 2 diabetes on these drugs did not increase risk of osteoporotic fractures

Absolute risk was low for patients receiving zoledronic acid versus denosumab